drugset / Trial / NCT06228846
An Phase I Study of YY001 in Patients with Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The safety and tolerability of YY001 in the treatment of patients with advanced solid tumors were evaluated, and the possible dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) or recommended phase II clinical dose (RP2D) were observed.
Timeline
- Start
- 2022-07-14
- Primary completion
- 2024-04-30
- Completion
- 2024-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YY001 | Protein / enzyme biologic | — | Oral |
Indications
No indication recorded.